About Us
about us
Pathos is redefining DRUG DEVELOPMENT starting IN Oncology.
By combining large-scale multimodal patient data with proprietary AI, Pathos helps identify which patients are most likely to benefit, increasing probability of success and accelerating high confidence Go/No-Go decisions.
the result?
A scalable, repeatable, patient-centered model for drug development that delivers smarter treatments, greater success, and stronger investor returns.
who we are
pathos core values
integrity
Data-driven, transparent decisions that put science first.
innovation
Harnessing AI and multimodal data to build a smarter model for drug development.
collaboration
Partnering with pharma, biotech, academia, and investors to bring therapies to patients.
resilience
Persevering through setbacks to deliver lasting progress in oncology.
empathy
Shaped by lived cancer experience; we lead with humanity.
Our mission starts with people. Join the team transforming how new therapies are developed, bringing better treatments to the patients that need them most.
The Pathos Story
Pathos was founded at the intersection of technology, oncology, and lived experience.
Pathos was founded in 2022 by Eric Lefkofsky and Ryan Fukushima, after they realized that AI could have a profound impact on drug discovery and development. In 2025, Iker Huerga, cancer survivor and biotech veteran, joined as CEO to focus on one mission: get the right therapies to the right patients, sooner.
Drawing on decades of leadership at Tempus and AstraZeneca, Pathos recognized that combining millions of patient records with proprietary AI could rewrite that story.
Today, Pathos uses this model to identify the right patients, design adaptive trials, and run them with small AI-enabled teams.
Each program teaches the next — making the system faster, smarter, and more precise.
mission & vision
Our mission is to transform drug development using proprietary patient data and AI to dramatically improve trial success rates and bring new hope to patients who fail traditional therapies.
We see a future where every patient has a real chance at the right treatment because drug development is data-guided, patient-centered, and repeatable. A new standard for how therapies are discovered, tested, and delivered.
The Future of Pathos
Pathos is building the blueprint for a new era of biopharma, one where data, intelligence, and humanity work in concert.
In this future, every trial begins with clarity.
Where drug development is no longer a gamble but a guided science, a living system that improves with every discovery.
For patients, it means more hope. For partners, it means more certainty. For the industry, it means transformation from reactive to intelligent, from incremental to exponential.
our team
Together, we’re redefining what’s possible in drug development, turning data into discovery, and discovery into hope.
Leadership
Board of Directors
The Team
Leadership Team
Iker Huerga
CHIEF EXECUTIVE OFFICER AND BOARD MEMBER
Iker Huerga is the Chief Executive Officer of Pathos AI, where he leads the company’s mission to transform drug development through artificial intelligence. A seasoned biotech entrepreneur and AI leader, Iker brings over two decades of experience at the intersection of machine learning and oncology. Prior to joining Pathos, he served as Chief Data Scientist for Oncology R&D at AstraZeneca and as EVP at Tempus Labs. He has founded and successfully exited multiple AI-driven oncology startups and is recognized for pioneering work in applying multimodal AI to clinical trial design, biomarker discovery, and precision medicine.
Eric Schadt, Ph.D.
CHIEF SCIENCE OFFICER
Eric Schadt joined Pathos as Chief Scientific Officer and maintains a continuing faculty role at the Icahn School of Medicine at Mount Sinai (ISMMS). Prior to joining Pathos, Schadt was founding CEO and then chief R&D officer of Sema4 (now GeneDx), a next-generation, information-driven precision medicine company developing advanced genomic testing solutions to enable genomic medicine.
He has also served as chairman of the Department of Genetics and Genomic Sciences and founding director of the Icahn Institute for Genomics and Multiscale biology at ISMMS (2012-2018), as CSO of Pacific Biosciences (2009-2011), and varying scientific leadership roles at Merck, Rosetta Inpharmatics, and Roche.
Schadt has his undergraduate training in computer science and math from Cal Poly, San Luis Obispo, a Master’s in Pure Mathematics from UC Davis, and a PhD in Biomathematics from UCLA. He is considered a pioneer in developing and applying integrative computational biology methods to very large-scale data to further our understanding of disease and wellness (co-author of more than 500 peer-reviewed papers and an h-index of 146).
Matt De Silva
CHIEF OPERATING OFFICER
Matt De Silva joined Pathos as Chief Operating Officer. Previously he was founder and chairman of Notable Labs, a clinical-stage precision therapeutics company developing predictive ex vivo technology to identify, from a blood sample taken before treatment, whether a patient will positively respond to a given treatment. He is also currently a Venture Partner at Builders VC, a Series A and seed-focused venture firm based in San Francisco. De Silva focuses on the healthcare and life science investment practice.
Prior to Notable, which he ran as CEO from 2014 to 2020, he was a macro hedge fund portfolio manager at Peter Thiel’s family office Thiel Capital. Prior to Thiel Capital, De Silva was an analyst at Bank of America Merrill Lynch. He graduated from Cornell University in Applied Economics and Management and was the captain of the cross country team.
Explore career opportunities
If you’re driven by purpose, grounded in science, and inspired by impact, we want to hear from you.